Skip to main content
SpringerLink
Log in

Expression of Cortactin Correlates with a Poor Prognosis in Patients with Stages II–III Colorectal Adenocarcinoma

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery

Abstract

Background

The present study was designed to specifically investigate the clinicopathological role of expression of cortactin, as well as the correlation with clinical outcomes in stages II–III colorectal cancer (CRC).

Methods

Two hundred and five stages II–III CRC patients were included in this study. Formalin-fixed paraffin-embedded specimens were stained for cortactin and the correlation between the staining, its clinicopathological parameters, and its prognostic power were analyzed statistically.

Results

Of the 205 patients studied, 113 cases (55.1%) were strongly positive for cortactin. Cortactin expression correlated with tumor invasion (P = 0.018), histological grade (P = 0.004), and preoperative CEA level (P < 0.001). In univariate analysis, tumor invasion, American Joint Committee on Cancer (AJCC) stage, lymphovascular invasion, preoperative CEA level, and cortactin expression were significant prognostic factors for disease-free survival (P = 0.034, 0.009, 0.043, 0.004, and 0.004, respectively), while for overall survival, tumor invasion, AJCC stage, pathologic grade, preoperative CEA level, and cortactin expression were significant prognostic factors (P = 0.003, 0.008, 0.038, 0.017, and <0.001, respectively). In multivariate analysis, tumor invasion, preoperative CEA level, and cortactin expression maintained their independent prognostic influence on disease-free survival (P = <0.001, 0.003, and 0.008, respectively). However, tumor invasion, AJCC stage, and cortactin expression influenced overall survival (P = 0.036, <0.001, and 0.004, respectively).

Conclusions

Cortactin may be a good biomarker to be applied in the clinical setting to predict the prognosis of patients with completely resected pathologic stages II–III CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ottaiano A, Franco R, Aiello Talamanca A, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res. 2006;12:2795–803.

    Article  CAS  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.

    Article  PubMed  Google Scholar 

  3. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997;40:15–24.

    Article  CAS  PubMed  Google Scholar 

  4. Cerottini JP, Caplin S, Pampallona S, et al. Prognostic factors in colorectal cancer. Oncol Rep. 1999;6:409–14.

    CAS  PubMed  Google Scholar 

  5. Zafirellis K, Agrogiannis G, Zachaki A, et al. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res. 2008;147:99–107.

    Article  CAS  PubMed  Google Scholar 

  6. van Rossum AG, Moolenaar WH, Schuuring E. Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res. 2006;312:1658–70.

    Article  PubMed  Google Scholar 

  7. Weaver AM, Karginov AV, Kinley AW, et al. Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol. 2001;11:370–4.

    Article  CAS  PubMed  Google Scholar 

  8. Weaver AM. Cortactin in tumor invasiveness. Cancer Lett. 2008;265:157–66.

    Article  CAS  PubMed  Google Scholar 

  9. Ormandy CJ, Musgrove EA, Hui R, et al. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003;78:323–35.

    Article  CAS  PubMed  Google Scholar 

  10. Schuuring E. The involvement of the chromosome 11 q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes—a review. Gene. 1995;159:83–96.

    Article  CAS  PubMed  Google Scholar 

  11. Tsai WC, Jin JS, Chang WK, et al. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. J Histochem Cytochem. 2007;55:955–62.

    Article  CAS  PubMed  Google Scholar 

  12. Yuan BZ, Zhou X, Zimonjic DB, et al. Amplification and overexpression of the EMS 1 oncogene, a possible prognostic marker, in human hepatocellular carcinoma. J Mol Diagn. 2003;5:48–53.

    CAS  PubMed  Google Scholar 

  13. Greer RO Jr, Said S, Shroyer KR, et al. Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma. Oral Oncol. 2007;43:735–41.

    Article  CAS  PubMed  Google Scholar 

  14. Lee YY, Yu CP, Lin CK, et al. Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters. Dis Markers. 2009;26:9–18.

    CAS  PubMed  Google Scholar 

  15. Schuuring E, Verhoeven E, van Tinteren H, et al. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 1992;52:5229–34.

    CAS  PubMed  Google Scholar 

  16. McCarty KS Jr, Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46:4244s–8s.

    PubMed  Google Scholar 

  17. Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187–220.

    Google Scholar 

  18. Levy M, Visokai V, Lipska L, et al. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma. 2008;55:138–42.

    CAS  PubMed  Google Scholar 

  19. Zhang LH, Tian B, Diao LR, et al. Dominant expression of 85-kDa form of cortactin in colorectal cancer. J Cancer Res Clin Oncol. 2006;132:113–20.

    Article  PubMed  Google Scholar 

  20. Rodrigo JP, García-Carracedo D, García LA, et al. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol. 2009;217:516–23.

    Article  CAS  PubMed  Google Scholar 

  21. Hofman P, Butori C, Havet K, et al. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br J Cancer. 2008;98:956–64.

    Article  CAS  PubMed  Google Scholar 

  22. Daly RJ. Cortactin signalling and dynamic actin networks. Biochem J. 2004;382:13–25.

    Article  CAS  PubMed  Google Scholar 

  23. Norton L, Massagué J. Is cancer a disease of self-seeding? Nat Med. 2006;12:875–8.

    Article  CAS  PubMed  Google Scholar 

  24. Wood CB, Ratcliffe JG, Burt RW, et al. The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. Br J Surg. 1980;67:46–8.

    Article  CAS  PubMed  Google Scholar 

  25. Wichmann MW, Muller C, Lau-Werner U, et al. The role of carcinoembryonic antigen for the detection of recurrent disease following curative resection of large-bowel cancer. Langenbecks Arch Surg. 2000;385:271–5.

    Article  CAS  PubMed  Google Scholar 

  26. Chau I, Allen MJ, Cunningham D, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol. 2004; 22:1420–9.

    Article  CAS  PubMed  Google Scholar 

  27. McCall JL, Black RB, Toouli J, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum. 1994;37:875–81.

    Article  CAS  PubMed  Google Scholar 

  28. Wanebo HJ, Rao B, Pinsky CM. The use of preoperative carcinoembryonic antigen level as a prognostic indicator to complement pathological staging. N Engl J Med. 1978;299: 448–51.

    CAS  PubMed  Google Scholar 

  29. Wichmann MW, Lau-Werner U, Mu¨ ller C, et al. Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res. 2000;20:4953–5.

    CAS  PubMed  Google Scholar 

  30. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23:338–51.

    PubMed  Google Scholar 

  31. Lipská L, Visokai V, Levý M, et al. Tumor markers in patients with relapse of colorectal carcinoma. Anticancer Res. 2007;27:1901–5.

    PubMed  Google Scholar 

  32. Watine J, Miedouge M, Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: a systematic review. Dis Colon Rectum. 2001;44:1791–9.

    Article  CAS  PubMed  Google Scholar 

  33. Wiratkapun S, Kraemer M, Eu KW, et al. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum. 2004;44:231–5.

    Article  Google Scholar 

  34. Takagawa R, Fujii S, Ohta M, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15:3433–9.

    Article  PubMed  Google Scholar 

  35. Newland RC, Chapuis PH, Pheils MT, et al. The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer. 1981;47:1424–9.

    Article  CAS  PubMed  Google Scholar 

  36. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al. American joint committee on cancer prognostic factors consensus conference: colorectal working group. Cancer. 2000;88:1739–57.

    Article  CAS  PubMed  Google Scholar 

  37. Chuma M, Sakamoto M, Yasuda J, et al. Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol. 2004;41:629–36.

    Article  CAS  PubMed  Google Scholar 

  38. Gibcus JH, Mastik MF, Menkema L, et al. Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer. 2008;98:950–5.

    Article  CAS  PubMed  Google Scholar 

  39. Li X, Zheng H, Hara T, et al. Aberrant expression of cortactin and fascin are effective markers for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Int J Oncol. 2008;33:69–79.

    PubMed  Google Scholar 

  40. Lin CK, Su HY, Tsai WC, et al. Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: correlation with clinicopathological parameters. Dis Markers. 2008;25:17–26.

    CAS  PubMed  Google Scholar 

  41. Hsu NY, Yeh KT, Chiang IP, et al. Cortactin overexpression in the esophageal squamous cell carcinoma and its involvement in the carcinogenesis. Dis Esophagus. 2008;21:402–8.

    Article  CAS  PubMed  Google Scholar 

  42. Rodrigo JP, García-Carracedo D, García LA, et al. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol. 2009;217:516–23.

    Article  CAS  PubMed  Google Scholar 

  43. Hsu KF, Lin CK, Yu CP, et al. Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis Esophagus. 2009;22:402–8.

    Article  PubMed  Google Scholar 

  44. Lin CK, Chao TK, Yu CP, et al. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS. 2009;117:162–75.

    Article  CAS  PubMed  Google Scholar 

  45. Hirakawa H, Shibata K, Nakayama T. Localization of cortactin is associated with colorectal cancer development. Int J Oncol. 2009;35:1271–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The research was supported in part by the National Natural Science Foundation of China (No.30772106).

Conflict of interest statement

None declared.

Author information

Authors and Affiliations

  1. Department of General Surgery, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine, No. 197, Ruijin Er Rd, Shanghai, 200025, People’s Republic of China

    Jian-hua Cai, Ren Zhao, Fang-jun Wan, Kun Liu, Xiao-pin Ji & Zheng-gang Zhu

  2. Department of Pathology, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China

    Xiao-long Jin & Yan-bo Zhu

  3. Department of General Surgery, The Affiliated Hospital to Nantong University, No. 20, Xisi Rd, Nantong, 226001, People’s Republic of China

    Jian-wei Zhu

Authors
  1. Jian-hua Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ren Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian-wei Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-long Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fang-jun Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao-pin Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yan-bo Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zheng-gang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ren Zhao.

Additional information

The authors have no commercial, proprietary, or financial interest in the products or companies described in this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cai, Jh., Zhao, R., Zhu, Jw. et al. Expression of Cortactin Correlates with a Poor Prognosis in Patients with Stages II–III Colorectal Adenocarcinoma. J Gastrointest Surg 14, 1248–1257 (2010). https://doi.org/10.1007/s11605-010-1247-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-010-1247-2

Keywords

Search

Navigation